Samsung Biologics Signs Contract for Contract Development with Chinese Bio Venture

[Asia Economy Reporter Cho Hyun-ui] Samsung Biologics has signed a contract for cell line development outsourcing (CDO) of the non-small cell lung cancer and triple-negative breast cancer treatment candidate substance 'GQ1003' with the Chinese bio-venture company Jin Quantum.

On the 2nd, Samsung Biologics announced that through this cooperation, it plans to continue additional CDO collaborations for multiple development pipelines owned by Jin Quantum.

Jin Quantum is a Chinese bio-venture developing various tumor treatments based on antibody-drug conjugates (ADC). While it signed a CDO contract with a Chinese company for its first new drug candidate (GQ1001), it switched its outsourcing partner to Samsung Biologics starting from the second development substance (GQ1003).

Samsung Biologics has recently been expanding its presence in the Chinese bio market by successfully collaborating with bio-ventures in the Greater China region. It analyzed that the strategy of maximizing customer satisfaction through CDO technological innovation was effective in entering the Chinese bio market.

Kim Tae-han, CEO of Samsung Biologics, said, "Our efforts to maximize customer satisfaction through the high capabilities of CDO services are also resonating in the Chinese bio market," adding, "Through collaboration with major promising Chinese bio-ventures, we will be able to carry out more projects in the Greater China region as well as the global market."

This content was produced with the assistance of AI translation services.